Enanta Pharmaceuticals, Inc. (ENTA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 122 | 97 | 86 | 79 | 68 | 65 | 65 | 65 |
| Operating profit | $m | -85 | -59 | ||||||
| Net profit | $m | -36 | -79 | -122 | -134 | -116 | -82 | -63 | -49 |
| EPS reported | $ | -3.84 | -2.41 | ||||||
| Operating cashflow per share | $ | -0.90 | -1.21 | ||||||
| Capex per share | $ | 0.60 | 0.06 | ||||||
| FCF per share | $ | -1.51 | -1.27 | ||||||
| Free cash flow | $m | -32 | -37 | ||||||
| Net debt | $m | -46 | -190 | ||||||
| Book value equity | $m | 65 | 101 | ||||||
| Book value per share | $ | 3.03 | 3.47 | ||||||
| Number of shares | m | 21.34 | 29.09 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.95 | 2.53 | ||||||
| P/S LTM | x | 3.91 | 3.91 | ||||||
| P/FCF LTM | x | -7.94 | -6.91 | ||||||
| EV/EBITDA LTM | x | -5.99 | -9.12 | ||||||
| EV/Sales LTM | x | 6.49 | 6.20 | ||||||
| Earnings Yield LTM | % | -32.06% | -16.52% | ||||||
| FCF Yield | % | -12.60% | -14.46% | ||||||
| Quality | |||||||||
| ROE | % | -126.53% | -61.84% | ||||||
| ROIC | % | -31.44% | -23.81% | ||||||
| Operating margin | % | -1.31% | -89.99% | ||||||
| Gross margin | % | +92.98% | +98.15% | ||||||
| FCF/Sales | % | -49.24% | -56.60% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -3.42% | -3.51% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.16 | -0.66 | ||||||
| Net Debt/EBITDA | x | -2.38 | -0.48 | ||||||
| EBIT/Net interest | x | -11.11 | -4.55 | ||||||
| Net debt/market cap | % | +56.05% | 0.00% | ||||||
| Net debt/Equity | x | -0.71 | -1.88 | ||||||
| Gross debt/equity | x | 3.11 | 0.55 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Enanta Pharmaceuticals, Inc. (ENTA)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free